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Abstract
Background: Infection with HIV, which culminates in the establishment of a latent
proviral reservoir, presents formidable challenges for ultimate cure. Building on the
hypothesis that ex-vivo or even in-vivo abolition or disruption of HIV-gene/genome-
action by target mutagenesis or excision can irreversibly abrogate HIV’s innate fitness
to replicate and survive, we previously identified the isoschizomeric bacteria
restriction enzymes (REases) AcsI and ApoI as potent cleavers of the HIV-pol gene (11
and 9 times in HIV-1 and 2, respectively). However, both enzymes, along with others
found to cleave across the entire HIV-1 genome, slice (SX) at palindromic sequences
that are prevalent within the human genome and thereby pose the risk of host
genome toxicity. A long-term goal in the field of R-M enzymatic therapeutics has
thus been to generate synthetic restriction endonucleases with longer recognition
sites limited in specificity to HIV. We aimed (i) to assemble and construct zinc finger
arrays and nucleases (ZFN) with either proviral-HIV-pol gene or proviral-HIV-1 whole-
genome specificity respectively, and (ii) to advance a model for pre-clinically testing
lentiviral vectors (LV) that deliver and transduce either ZFN genotype.
Methods and Results: First, we computationally generated the consensus sequences
of (a) 114 dsDNA-binding zinc finger (Zif) arrays (ZFAs or ZifHIV-pol) and (b) two zinc-
finger nucleases (ZFNs) which, unlike the AcsI and ApoI homeodomains, possess
specificity to >18 base-pair sequences uniquely present within the HIV-pol gene
(ZifHIV-polFN). Another 15 ZFNs targeting >18 bp sequences within the complete HIV-1
proviral genome were constructed (ZifHIV-1FN). Second, a model for constructing
lentiviral vectors (LVs) that deliver and transduce a diploid copy of either ZifHIV-polFN
or ZifHIV-1FN chimeric genes (termed LV- 2xZifHIV-polFN and LV- 2xZifHIV-1FN,
respectively) is proposed. Third, two preclinical models for controlled testing of the
safety and efficacy of either of these LVs are described using active HIV-infected
TZM-bl reporter cells (HeLa-derived JC53-BL cells) and latent HIV-infected cell lines.
Conclusion: LV-2xZifHIV-polFN and LV- 2xZifHIV-1FN may offer the ex-vivo or even in-
vivo experimental opportunity to halt HIV replication functionally by directly
abrogating HIV-pol-gene-action or disrupting/excising over 80% of the proviral HIV
DNA from latently infected cells.
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-The global challenge of human immunodeficiency virus (HIV) infection
Human infection with the retrovirus-human immunodeficiency virus (HIV) causes
acquired immunodeficiency syndrome (AIDS) [1]. Over a quarter a century since the
description of the first clinical cases of AIDS, HIV/AIDS remains a global health chal-
lenge [2,3]. There are now over 33 million people currently infected with HIV world-
over, and 25 million lives have already been lost to AIDS. Despite the advent of a
powerful regimen of highly active anti-retroviral therapy (HAART) to treat HIV/AIDS,
HAART has its limitations [4,5]. Specifically, while HAART targets actively replicating
HIV, latent-HIV infection, particularly proviral HIV DNA integrated with resting CD4
+ve cells, ultimately acts as a source of rebound viremia once treatment is stopped.
Recent reports suggest that the reservoir of latent proviral HIV infection may extend
beyond just the experimentally demonstrated CD4+ resting memory cells to include
cells of the macrophage, natural-killer, dendrite, astrocyte and bone marrow progenitor
lineages [6,7]. Overall, in the absence of a vaccine that is 100% effective, novel strate-
gies to tackle the unique challenge of latent HIV infection among patients on HAART
are urgently sought [7]. Although different mechanisms for the maintenance of reser-
voirs of latent HIV-infection have been advanced, the spectrum of emerging trial anti-
HIV latency ‘pro-drugs’ is largely limited to those agents functioning via the awakening
of resting host (CD4+ memory) cells; a strategy primarily meant to exorcise the latent
provirus [5,6]. Specifically, most of the trial anti-HIV latency pro-drugs (operating by
non-specific stimulation of T cell receptors, TCR) function either globally via nuclear
factor of activated T cells (NFAT) and protein C-kinase (PCK), or specifically via
reductive oxidative substrates (ROS) and cytokines such as tumor necrotic factor-alpha
(TNF-a) and interleukin-7 [8-11].
-The alternative option of directly disrupting or abolishing HIV gene expression
In 1999, I [12] first proposed the possibility of using the anti-phage DNA machinery
inherent in bacteria – the restriction modification (R-M) system (itself a primitive
anti-viral immunity) - as a model for devising eukaryotic virus gene therapies. Over the
past 10 years, I and colleagues [13,14] have identified several bacterially-derived restric-
tion enzymes with potential to cleave the DNA of human-infecting viruses, including
frequency and site mapping of HIV-1, HIV-2 and several other SIV gene-cleavage
using a proviral DNA model [15]. The isoschizomeric bacterial restriction enzymes
(REases) AcsI and ApoI have, for instance, specifically been found to possess high
potency to cleave (slice or disrupt) the HIV pol gene (11 and 9 times in HIV-1 and -2,
respectively) [15]. Both enzymes, along with their third isoschizomer XapI, cleave at
the palindromic site defined by the sequences 5’-RAATY-3’. Given the high incidence
within the human host genome of site-specific units (palindromes) similar to those of
the REases identified, matters of in-situ safety have proven a priority that is difficult to
address, limiting our prior attack-models to the extracellular space [14,16-21]. Specifi-
cally, because of the smaller sizes of phage genomes, bacteria evolve to select for R-M
systems with small recognition sites (4-6 bp), since these sites occur more frequently
in phages. However, this feature - a high incidence of palindromes - also renders the
human genome highly susceptible to REase-activity. Therefore, a long-term goal in the
field of R-M enzymatic therapeutics has been to generate synthetic restriction
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mutating or engineering existing enzymes.
Zinc Finger Nuclease technology and its applicability in antiviral gene therapy
development
Zinc finger nucleases - ZFNs - which are artificial, hybrid restriction enzymes created
by covalently linking a DNA-binding zinc finger (Zif) domain (composed of three to
six finger-arrays) to the non-specific DNA cleavage domain (or simply FN)o ft h eF l a -
vobacterium Okeanokoites bacterial restriction endonuclease-FokI, have recently
become a powerful tool for either primarily editing host genomes to halt viral infectiv-
ity, or secondarily targeting incoming or established viral genomes [22-30]. On the one
hand, Perez et al. [27], using engineered ZFNs targeting human CCR5, previously
demonstrated the establishment of HIV-1 resistance in CD4+ T cells through genera-
tion of a double-strand break (DSB) at predetermined sites in the CCR5 coding region
upstream of the natural CCR5D32 mutation. More recently, Holmes et al. [28] demon-
strated control of HIV-1 infection within NSG mice transplanted with human hemato-
poietic stem/progenitor cells modified by zinc-finger nucleases targeting CCR5. On the
other hand, with the intent of disrupting incoming viral genomes, Gross et al.[ 2 9 ] ,
have recently demonstrated homing (mega-) endonuclease-mediated inhibition of
HSV-1 infection in cultured cells. Indeed, Cradick et al. [30] had previously shown
that zinc finger nucleases could equally offer a novel therapeutic strategy for targeting
Hepatitis B Virus DNAs.
On the basis of the above advances in the field of ZFN technology, which permit the
generation of synthetic restriction enzymes that are expressible within the human gen-
ome without causing functional or structural-genome toxicity, we postulated that syn-
thetic zinc finger nucleases (ZFNs) with specificity to > 18 bp- palindromic sequence
within the HIV-pol gene, unlike the 5’-RAATY-3’ five-bp targeted by AcsI and ApoI,
can specifically disrupt the HIV-pol gene with no toxicity-risk to the human genome
[25-30]. Therapeutically, observing that theH I V - p o lg e n e( ~ 3 , 1 8 2b a s ep a i r s ) ,w h i c h
codes for the enzymes reverse transcriptase (RT), integrase and protease, is an indis-
pensable section of the HIV genome for viral replication and survival, ex-vivo or even
in-vivo disruption or abolition of HIV-pol should result in irreversible abrogation of
HIV’s innate fitness to replicate and survive [1]. Alternatively, however, one may opt to
target the entirety or most of the proviral genome for either disruption or excision.
While inhibition of HIV replication in-vivo using small artificial molecules modified to
harness the target DNA-binding mechanism inherent in zinc finger (ZF) domains as a
strategy to repress HIV transcription has previously been reported by Segal et al. [31]
and Eberhardy et al. [32], respectively, ZFN-based disruption or abolition of HIV genes
has yet to be reported. In other words, this work, unlike previous ZFN-based strategies
aiming to cure HIV by targeting the host pathways, is an attempt to attack and modify
the HIV pathway directly using ZFN technology.
The goal of this work was to identify and engineer, respectively, (i) HIV-pol gene and
HIV-1 whole genome specific ZF arrays (ZFAs) and (ii) ZF-nucleases (ZFNs); as well as
model construction and pre-clinical testing of lentiviral vectors (LVs) that deliver and
transduce a diploid copy of either HIV-specific ZFN genotype.
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Assembly of HIV-pol gene/HIV-1-proviral -dsDNA binding zinc finger arrays and construct
of HIV-pol gene/HIV-1-proviral-dsDNA cleaving zinc finger nucleases
First, using the Zinc Finger Consortium’s software ZiFiT-CoDA-ZFA and the complete
FASTA sequences of the SIV/HIV-pol gene [Genbank: NC_001870.1 > gi|
9629914:1714-4893], we assembled 114 ZFA with unique specificity to 9 bp sequences
within the SIV/HIV-pol gene. The ZiFit software operates on algorithms primarily
build by researchers from the Barbas lab [33,34] with minimal modifications [33-36].
Throughout our computational context-dependent assembly (CoDA) experiments, the
ZiFiT software was set at default setting and the exon/intron case-sensitivity algorithm
turned to its ON-mode, thereby allowing us to distinguish between intron and exon
sequences by denoting exons as uppercase and introns as lowercase [36]. These 114
SIV/HIV-pol gene specific ZFAs comprise three zinc finger (ZF) proteins linked
together. Overall, each ZF is a protein motif that has two beta strands and an alpha
helix [23-26]. The beta strands and alpha helix are stabilized by coordination of a zinc
ion mediated by pairs of conserved cysteinea n dh i s t i d i n er e s i d u e s .R e s i d u e s1t o6o f
the alpha-helix (numbered relative to the start of the helix) are responsible for the spe-
cific recognition of triplets of DNA sequences through the formation of base-specific
contacts in the major groove of the double-stranded target DNA [37-41]. Thus, resi-
dues 1 to 6 within ZF alpha helices are denoted ‘recognition’ residues, and these are
listed in N- to C-terminal direction, while all other residues in the ZF are called the
‘backbone’. ZFs bind target DNA sites (in this case, within the SIV/HIV-pol gene)
through amino acids 1 to 6 of the ‘recognition’ alpha helix binding on to consecutive
nucleotides in DNA in the 3’ to 5’ direction, a reverse pattern that can be confusing
because the DNA target site is always numbered in the 5’ to 3’ direction, whereas
amino acid sequences are numbered from N to C terminus (reviewed in [37]). Multi-
ZF-arrays (like our three ZF-arrays) are generated by combining Finger 1 domains (F1)
and Finger 3 domains (F3) that have been preselected to bind their cognate target sites
in the context of the same Finger 2 domain (F2) [37]. Five of the 114 ZFAs generated
are shown in table 1(for all, see additional file 1). A graphic map of the distribution of
the recognition sites for the 114 multi-Zif-arrays obtained along the 3,182 bp length of
the SIV/HIV-pol gene is shown in Figure 1. These ZFAs may be useful in future for
purposes of directing novel or existing small artificial molecules to inhibit the SIV/
Table 1 Five of the 114 ZFAs with binding specificity to sites within the SIV/HIV-pol
gene
Position (n) Zif # target-DNA sequence Zif array a-Helix (F1;F2;F3)
21-32 1 31 tGCAGAGTGTc 21
31 aCGTCTCACAg 21
RHQHLKL; RQDNLGR; QSNVLSR
50-60 2 50 aGAAGACAGGg 60
50 tCTTCTGTCCc 60
RRAHLLN; DRGNLTR; QSNNLNR
1515-1525 56 1515 gGCAGAAGCAg 1525
1515 cCGTCTTCGTc 1525
RGQELRR; QQTNLTR; QGNTLTR
1518-1528 57 1518 aGAAGCAGAAt 1528
1518 tCTTCGTCTTa 1528
QGSNLAR; QSTTLKR; QRNNLGR
3156-3166 113 3156 cGGAGAGGCTa 3166
3156 gCCTCTCCGAt 3166
NKQALDR; RQDNLGR; QANHLSR
NOTE: n is a position on a 1-to-3182 base-pair scale of the SIV/HIV-pol gene total nucleotide content, such that n+1714
(genomic context of first bp in gene) = actual genomic context of the target DNA specificity for the ZFA.
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et al. [31] and Eberhardy et al. [32] to repress HIV transcription. Second, using the
alternate ZiFiT-CoDA-ZFN software set at default and adjusted to allow for a 5, 6, or
7b ps p a c e rr e g i o nplus the FASTA sequences of the SIV/HIV-pol gene, we con-
structed two ZFNs with specificity to the SIV/HIV-pol-gene (see table 2 and additional
file 2) [33-36]. These ZFNs cleave at positions approximately 1063/1089 and 1871/
1895 within the SIV/HIV-pol gene. Each arm of these dimeric 3-ZF-nucleases recog-
nizes nine base pairs (bp). This implies that the issuing ZFN dimer in-vivo will recog-
nize an 18 + (5, 6, or 7 spacer) nucleotide-long region [37]. For instance, the two
ZFNs in table 2 recognize, respectively, 25 and 23 bp within the HIV-pol gene. A gra-
phic map of the distribution of the recognition sites for these two ZFNs built along
t h eS I V / H I V - p o lg e n ei ss h o w ni nF i g u r e2 .U s i n gt h e s et w oZ F N s ,w ea r g u et h a ti t
m a yb ep o s s i b l et ot a r g e ta n da b r o g a t et h e SIV/HIV-pol gene by inducing double
strand breaks (DSB) that can lead to excision of the region between positions 1063/
1089 and 1871/1895 followed by non-homologous end-joining (NHEJ) [37]. Alterna-
tively, however, using a set of 15 ZFNs that we generated by similar methods, which
target and cleave within > 18 bp sequences of the entire HIV-1 genome [Genbank:
NC_001802.1; >gi|9629357] and are here denoted ZifHIV-1FN (see Figure 3 and addi-
tional file 3), one may opt to excise over 80% of the latent provirus. Overall, using the
PCR technique described by Kim et al. [22], and primers for gene sequences of both
the DNA-cleavage domain of the Fok I endonuclease (FN: derived from Flavobacterium
Okeanokoites and belonging to the type IIS class) and the ZifHIV-pol or ZifHIV-1 DNA-
binding domain (see Table 2); fusion of the two sequences (ZifHIV-pol +FN or ZifHIV-1
+FN) to yield a haploid copy of the hybrid, chimeric ZFN (ZifHIV-polFN or ZifHIV-1 FN)
gene with HIV-pol gene/HIV-1 provirus specificity can be achieved in a bacteria plas-
mid. This intermediary step is necessary for cloning and biochemical characterization of
Figure 1 A graphic map of the distribution of the recognized target DNA sites by the 114 multi-
Zif-arrays, along the entire length of the SIV/HIV-pol-gene. The figure offers a detailed graphics
illustration of the distribution of target DNA sites along the full 3,182 bp lengths of the SIV/HIV-pol gene
recognized by all 114 multi-Zif-arrays. For details, see Table 1 and Additional file 1.
Table 2 The 2 ZFNs cleaving >18 bp sequences specifically within the HIV-pol gene
Zinc Finger Nuclease (ZFN) Left Fn; triplet- a-Helix Right Fn; triplet- a-Helix
-target HIV-pol-gene 5’
ZFN-unknown-SP-7-1
1063 gTTCTGCCTCAGGGATGGAAGGGGTCa 1089 F1; QGSNLAR;(GAA) F1; TKSLLAR;(GTC)
1063 cAAGACGGAGTCCCTACCTTCCCCAGt 10891 F2; QSTTLKR;(GCA) F2;RREHLVR;(GGG)
F3; RGDNLNR;(GAG) F3;QDGNLGR;(GAA)
-target HIV-pol-gene 3’
ZFN-unknown-SP-5-1
1871 cAACACCACCGCTAGTAAGATTAGt 1895 F1; AATALRR;(GTT) F1; RSHNLRL;(TAG)
1871 gTTGTGGTGGCGATCATTCTAATCa 1895 F2; EAHHLSR;(GGT) F2; VRHNLTR;(GAT)
F3; IRHHLKR;(GGT) F3; QQGNLQL;(TAA)
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final cloned hybrid, chimeric ZFN (say-2xZifHIV-polFN) gene and its expressed protein
(REase) can respectively be done by (i) sequencing the target region of interest within
the plasmid, and/or (ii) gel-electrophoretic extraction and biophysical profiling of the
purified protein to determine its instability index, aliphatic index, theoretical pI, in vivo
half life and grand average hydropathy (GRAVY) [13,22]. These data are relevant for
estimating the in-vivo ideal temperatures of function, solubility patterns in aqueous
solution, and life-expectancies of the functional ZFN genotypes following expression in-
vivo. The specificity of these ZFAs and ZFNs can also further be enhanced through in-
vivo modifications to the cleavage domain in order to generate a hybrid capable of
functionally interrogating the ZFN dimer interface so as to prevent homodimerization,
while still enhancing the efficiency of cleavage [38]. Further optimization within a bac-
teria-one hybrid (B1H) or yeast-one hybrid (Y1H) system may also be required [39].
Modeling the construct of lentiviral vectors for the specific delivery of a diploid copy of
Zif-FN into CD4+ve cells
Third, lentiviral vectors (LVs)-by virtue of their unique ability to infect CD4 + cells
inclusive of bone-marrow progenitor cell-lines, form an ideal vehicle for delivering and
transducing the diploid copy of the SIV/HIV-pol gene/HIV-1 provirus-specific ZFNs
(2xZifHIV-polFN and 2xZifHIV-1 FN) identified and cloned above[7,40-42]. Over the past
10 years of our work with REases, LVs have emerged as potent and versatile vectors
for ex vivo or in vivo gene transfer into dividing and non-dividing cells [15,41]. The lat-
ter – ability to infect non-dividing cells - presents a unique opportunity when targeting
of proviral HIV DNA in resting CD4 + memory cells is considered [5,6,42]. Moreover,
in conjunction with zinc-finger nuclease technology and HIV, LVs allow for site-speci-
fic gene correction or addition in predefined chromosomal loci where proviral HIV
resides [5,40,43]. Therefore, although ot h e rv e c t o r ss u c ha sa d e n o v i r u s e sa n dg-retro-
viral vectors can be used to deliver either HIV-specific ZFN genotype, the unique
advantages offered by LVs plus several design improvements underscore the safety and
efficacy of LVs, with significant implications for proviral HIV reservoir targeting gene
therapy in humans [43]. Specifically, robust phenotypic correction of diseases in mouse
models has been achieved, paving the way toward the first clinical trials. LVs can
Figure 2 A graphic map of the distribution of the target-DNA sites recognized by the two ZFNs
obtained along the entire length of the SIV/HIV-pol-gene. This figure offers a graphic map of the
distribution of target DNA sites recognized and cleaved by our two ZFNs, along the full 3,182 bp lengths
of the SIV/HIV-pol gene. For details, see Table 2 and Additional file 2.
Figure 3 A graphic map of the distribution of the target-DNA sites recognized by 15 ZFNs
obtained along the entire length of the HIV-1 genome. This figure offers a graphic map of distribution
of target DNA sites recognized and cleaved by the 15 ZFNs along the full 9,182 bp lengths of the HIV-1
genome. For details, see additional file 3.
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allowing for stable transgene expression upon hematopoietic reconstitution. LVs can
be pseudotyped with distinct viral envelopes that influence vector tropism and trans-
duction efficiency [43]. Nonetheless, our ultimate goal – expressing proviral HIV
DNA-specific Zif-FN within dividing and non-dividing CD4+ mammalian cell lines in-
vivo - calls for specialized LV constructs. First, because LVs are derived from HIV-1, a
human pathogen, it is critically important to ensure that the corresponding LV is repli-
cation-defective. The latest generation LV technology has several built-in safety fea-
tures that minimize the risk of generating replication-competent wild type human
HIV-1 recombinants. Typically, LVs are generated by trans-complementation whereby
packaging cells are co-transfected with a plasmid containing the vector genome and
the packaging constructs that encode only the proteins essential for LV assembly and
function. Lentiviral plasmid vectors are in principle constructed by deleting 5 of the 9
wild type HIV genes, specifically vif, vpr, vpu, nef and tat, leaving behind a gap-pol-rev
expression plasmid skeleton [42-44]. The rev gene, which binds to the rev-response
protein exportin (RRE) to enable nuclear transport of the lentivirus, is often replaced
by either a simian rev/RRE system or the Mason-Pfizer constitutive transport element
(CTE), which exploit other intra-cisternal type A elements (IAPE) such as the RNA
transport element (RTE) other than the rev/RRE complex to export lentivirus RNA out
of the nucleus [45]. Secondly, constructing the ultimate lentiviral plasmids encoding
either the LV-2xZifHIV-polFN or the LV-2xZifHIV-1FN genotype should exploit the
design advanced by Oh et al. [44] comprising the HIV 5’ long terminal repeat (LTR)
fused with the Rous Sarcoma Virus (RSV) U5 region, and containing the phosphogly-
cerokinase (PGK) promoter required to drive the expression of a diploid copy of the
hybrid bacterial, say the ZifHIV-polFN, chimeric gene (or simply LV-2xZifHIV-polFN parti-
cles). As a unique feature, a pair of splice donor (SD) and acceptor (SA) sites, the
XbaI/NotI REase specificity sites separated by a 2A peptide, is required to enable PCR-
based cloning of the diploid copy of the hybrid bacterial ZifHIV-polFN or ZifHIV-1FN
gene into the pHRSVcPGKnls backbone to yield the either LV-2xZifHIV-polFN or LV-
2xZifHIV-1FN transfer vector plasmid or particles as final products. Such multicistronic
constructs, in which several proteins are encoded by a single messenger RNA, are
commonly used in genetically engineered animals [45]. Although the use of an internal
ribosomal entry site (IRES) was previously favored for multicistronic constructs, Tichas
et al. [45] recently demonstrated the efficient use of the 2A peptide for bicistronic
expression and co-translational cleavage in transgenic mice. The final LV-particles can
then be produced recombinantly in large amounts by the known transient triple-plas-
mid transfection of 293T cells [40,42,44,46,47]. In practice, it is necessary that plasmids
are at this stage evaluated for their gene-delivery and transduction potential using the
protocols previously described by Oh et al. [44] and Mátrai et al. [42], but tailored to
ZFNHIV-pol before their packaging. Ultimately, packaging cells are transfected with the
lentiviral vector plasmid and three helper (packaging) constructs encoding Gag, Pol,
Rev, and VSV-G. Only the vector contains the packaging sequence Ψ,w h e r e a st h e
packaging constructs are devoid of Ψ. The LV is flanked by the 5’ and 3’ LTR
sequences that have promoter/enhancer activity and are essential for the correct
expression of the full-length vector transcript. The LTRs also play important roles in
reverse transcription and integration of the vector into the target cell genome. Overall,
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post-transcriptional regulatory element (WPRE), central polypurine tract (cPPT), and
Rev responsive element (RRE) are used. Assembled vector particles can then be har-
vested from the supernatant and, if required, subjected to further purification and con-
centration. Packaging LVs encoding different envelope genes only serves to allow for
production of distinct LV pseudotypes with different tropisms [42].
3. Testing the efficacy and safety of the lentiviral vectors delivering and transducing SIV/
HIV-pol-gene specific, ZFN
Thirdly and finally, preclinical models for controlled testing of the safety and efficacy
of LV- 2xZifHIV-polFN or LV- 2xZifHIV-1FN m a yb ed e v i s e du s i n geither active HIV-
infected TZM-bl reporter cells (HeLa-derived JC53-BL cells that express high levels of
CD4, CXCR4, and CCR5, and contain reporter cassettes for luciferase and b-galactosi-
dase, both driven by the HIV-1 long terminal repeat); or latent-HIV-infected J-Lat cell
lines that harbor a full-length HIV-1 genome that is transcriptionally competent and is
integrated within actively transcribed cellular genes, but is inhibited at the transcrip-
tional level [41,48]. Note, however, that the J-Lat cells may not offer us an appropriate
model of latency, and Oh et al. [49] have recently established two novel cell lines
latently infected with HIV-1 by limiting dilution cloning of resting A3.01 cells infected
with HIV-1. These represent an alternative and better option to J-Lat cells for studying
the molecular mechanisms of viral latency and development of anti-reservoir therapy
of HIV-1 infection. In the first instance, I propose the innoculation of a single-parent
culture of TZM-bl reporter cells on Dulbecco medium (DMEM), which is subsequently
divided into two: a test-daughter (td)s a m p l ea n dac o n t r o l - d a u g h t e r( cd) sample. The
td-sample is modified by transfection with, say, LV- 2xZifHIV-polFN to express ZifHIV-
polFN (the efficiency of ZifHIV-polFN expression must be tested here, say by ELISA
assays); the cd sample is left untreated. At time zero (T0), both td and cd samples are
infected with HIV at infectious doses of 0.1, 0.2, 0.3 million particles per unit, after
which they are cultured for a further 24-36 hours. The efficacy for abolition or disrup-
tion of HIV-pol gene expression can be measured by studying the level of abrogation
in HIV’s innate fitness to replicate and survive in-vivo, through measuring the level of
chemiluminescence from the reporter cassettes for luciferase and b-galactosidase
(expected to be diminished in td sample once ZifHIV-polFN is highly efficacious, since
reporter cassettes are driven by the HIV-1 long terminal repeat). This initial experi-
ment essentially offers a model for testing the primary prevention of HIV infection by
LV-2xZifHIV-polFN (a preventive vaccine mode). Safety should be evaluated by assaying
and comparing levels of inflammatory cytokines, apoptotic DNA ladders, and targeted
sequencing of proviral HIV integration hot spots (say via PCR amplification of the
HIV-LTR) within the TZM-bl reporter cells in td relative to cd-samples (no significant
differences are expected for a safe profile). In the second alternative scenario,u s i n g
either J-Lat or the Oh et al. [49] cell lines that offer us an in vitro model of HIV-1
latency, we can devise a model for testing the potency of LV-2xZifHIV-polFN towards
the end-goal of HIV therapeutic cure and latent provirus eradication [47]. Specifically,
a parent culture of J-Lat or Oh et al. [49] cells maintained on DMEM is divided into a
td- and cd- sample. As above, the td-sample is transfected with (say) LV-2xZifHIV-polFN
at time zero (T0) and the extent of ZifHIV-polFN expression again measured, say by
ELISA-assays, while the cd-sample is left untreated. The efficacy of LV-2xZifHIV-polFN
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latently infected cells through the abolition or disruption of HIV-pol gene/genome
action can be measured by studying the level of fluorescence (a marker of latent pro-
virus, and one expected to be low in the td-sample once ZifHIV-polFN are expressed and
efficacious); following the addition of agents that exorcise proviral HIV-DNA [5,8-11].
This assay should be facilitated by ensuring that the latent provirus integrated in the
Oh et al. [48] cell lines, as in J-Lat cells, also includes the GFP gene [48]. The latter
would provide us with a fluorescent marker of HIV-1 transcriptional activity. Again,
safety here can be evaluated by assaying and comparing levels of inflammatory cyto-
kines, apoptotic DNA ladders, and targeted sequencing of proviral HIV integration hot
spots (say via PCR amplification of HIV-LTR) within the J-Lat or Oh et al. [49] cells
in td relative to cd-samples (no significant differences are expected in respect of safety).
4. Availability: Databases and software
- The ZFN consortium CoDA-ZiFiT-ZFA/ZFN software and algorithms used are
available at the following url: http://www.zincfingers.org/scientific-background.htm
- The NCBI gene database hosting the HIV-pol gene and HIV-1 whole genome are
available at the following url:
(i)http://www.ncbi.nlm.nih.gov/nuccore/NC_001870.1
(ii) http://www.ncbi.nlm.nih.gov/nuccore/9629357?report=fasta
General discussion
I report here SIV/HIV-pol gene and HIV- 1w h o l eg e n o m es p e c i f i cz i n cf i n g e r
nucleases, which are proposed for use towards targeted HIV gene therapy. Specifically,
because of the notoriety and promiscuousness of HIV at evading previous therapeutic
and vaccine attempts, we - building on the bacterial R-M enzymatic machinery as a
primitive anti-viral model and prior work identifying bacterial REases against SIV/HIV
genomes - postulated that ex-vivo or even in-vivo disruption of viral gene action or
excision of over 80% of proviral HIV DNA from within infected cells can irreversibly
inactivate both active and latent virus [4-7,12-14]. The SIV/HIV-specific bacterial
REases previously identified towards this purpose also target short palindromic targets
present within the human genome and thereby carry the risk for toxicity [15]. Now,
however, in the wake of advances in zinc finger technology, I have assembled 114
ZFAs (Figure 1, Table 1, and Additional file 2) and constructed 2 ZFNs (Figure 2,
Table 2, and Additional file 2) with unique specificity to >18 bp sequences present
only within the SIV/HIV pol gene. In addition, another 15 ZFNs were constructed that
target and cleave within the >18 bp sequences present only within the proviral DNA of
t h ew h o l eH I V - 1g e n o m e( s e eF i g u r e3f o rg r a phic distribution of the cleavage sites
and pattern. For details of the latter, see additional file 3). It is therefore speculated
that lentiviral vectors carrying either genotype (LV-2xZifHIV-polFN or LV- 2xZifHIV-
1FN) may offer the ex-vivo or even in-vivo experimental opportunity to halt HIV repli-
cation functionally by directly-either abrogating HIV-pol gene action or excising over
80% of proviral HIV dsDNA from latently infected cells [40,42].
Several potential limitations are contingent on the above proposition that readers
s h o u l dt a k ei n t oa c c o u n t ,a st h e s em a yr e q u i r ea d d r e s s i n gb e f o r et h i st e c h n o l o g yi s
moved from the lab into human trials. First,t h ep o s s i b i l i t yo fg e n o m et o x i c i t y ,t h o u g h
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Page 9 of 13minimized by the shift from our prior REase model to hybrid ZFN prototypes, remains
and underlines the rationale for conducting the above suggested genome-safety profil-
ing [14,18,36]. In this regard, perhaps the HIV-pol gene or HIV-1 whole genome speci-
ficity of those 3-zinc finger nucleases identified in this study may benefit from further
modular enhancements towards 4, 5, or 6 finger arrays [37]. The specificity of such
multi-finger proteins can also be enhanced by in-vitro optimization using a bacteria-
one hybrid (B1H) or yeast-one-hybrid (Y1H) system [39]. Moreover, modifications to
the cleavage domain in order to generate a hybrid capable of functionally interrogating
the ZFN dimer interface so as to prevent homodimerization, while still enhancing the
efficiency of cleavage, are equally possible [38]. Second, clinical trails of lentiviral vec-
tors are still limited globally, a fact that may hinder the global use of the technology,
particularly within the low and middle income countries most affected by the HIV epi-
demic [2]. Outweighing these potential shortcomings, though, is that LV technology
has greatly improved over the past decade [40,42]. Moreover, LVs offer us the added
user-friendly advantage that they may be directly administered to patients via intrave-
nous (IV) or intra-osseous (IO) in-vivo routes and yet still effect a therapeutically ade-
quate gene delivery and transduction for HIV preventive or therapeutic purposes
(vaccines); though this may be less than the up-to-17% achieved by ex-vivo routes
[28,42]. Overall, for purposes of targeting latent proviral HIV reservoir, the likelihood
that in-vivo delivered LVs would ever find and effectively transduce a latently-infected
cell with the diploid copy of the ZFN remains to be established, considering that those
latently infected cells might be circulating randomly all around the body in the blood
[5,6]. Perhaps experiments to evaluate the efficiency and extent of in-vivo LV-delivery
using humanized mice, as Wilen et al. [43] recently did, and fluorescent labeled LVs,
may suffice here. Until such experiments establish these in-vivo LV-delivery routes as
adequate, however, the already proven ex-vivo alternative remains most viable
[27,28,43]. Alternatively, s i n c eo n l ya b o u t1i n1 , 0 0 0 , 0 0 0m e m o r yT - c e l l sa r el a t e n t l y
infected in the body, they are hard targets to hit by LVs delivered directly in-vivo,a n d
more strategies may be required, either to enhance the above-presented model or act
as completely novel in-vivo ZFN-delivery vehicles [42,43]. Also, the efficiency of tar-
geted mutagenesis by LVs delivered in this manner, which would have to be extremely
high in order to affect enough cells to be useful, remains questionable yet relevant to
know, since even a small residual reservoir of cells carrying the provirus would be suf-
ficient to restart a systemic infection [5,23-28]. One may, however, counter this reason-
ing by arguing that neither all nor any resting memory CD+ cells need to be modified
by LVs in order to halt the buildup of a re-infection functionally. Specifically, once the
newly emerging active (non-resting) CD4+ve cells from the progenitor cell-lines are all
resistant, any new HIV particles will have no active CD4+ cells to infect and propagate
in. In addition, there could be several proviral HIV integration sites in a single CD4+
cell genome, unlike the loci for host gene targets such as CCR5, and that presents
another challenge and yet an opportunity for LVs to wipe out HIV efficaciously from
within infected cells[5,6,27,28,42]. Despite all the above reservations surrounding the
efficiency of gene delivery associated with in-vivo relative to ex-vivo routes,w ec a n
maintain that further exploration of novel LV designs for in-vivo delivery may circum-
vent these obstacles and allow for a wider usability of these HIV gene- or genome-spe-
c i f i cZ F N sa st h e r a p e u t i c s ,p a r t i c u l a r l ysince this would eliminate the need for the
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quent transplantation [12,13,28]. That would make these treatments easily accessible to
people within resource-limited settings where HIV is most prevalent and the former
science is lacking. Induction of a type I interferon response that reduces LVs availabil-
i t yi sp o s s i b l e ,b u tt h i si sl i k e l yt ob ev e r y minimal among persons living with HIV or
AIDS who are in late stages of immunosuppression, while use of steroid or non-mye-
loablative preparative regimens may be required for those not yet immunocompro-
mised [50,51]. Third, HIV is notorious for evolving mutations that lead to resistance to
drugs, and ZFNs are no exceptions. For instance, it is possible that HIV, by evolving
single base substitutions, may evade the specificity of REases [4,5]. Nonetheless, we
note that because many mutations leading to resistance to HAART are single point
mutations, and ZFN-resistance mutations may need to accrue in >18 bp, such cumula-
tive substitutions are likely to be selectively disfavored since the progeny virus posses-
sing them is phenotypically disadvantaged [4,52]. Last but not least, many lentiviral
vector plasmids exploit a gap-pol core as the expression plasmid-skeleton, which raises
the possibility that the LV-plasmid’s pol-gene component may itself be targeted by our
HIV specific Zinc Finger Nucleases, particularly ZifHIV-polFN. To eliminate this possibi-
lity, perhaps the design for the ZifHIV-polFN genotype carrying LV-plasmids should
exploit constructs recently described by Oh et al. [44], which comprise just the HIV 5’
long terminal repeat fused with the Rous Sarcoma Virus U5 region and use the phos-
phoglycerokinase (PGK) promoter to drive the expression of the diplod copy of ZifHIV-
polFN. Only the cis-acting DNA element known as the central polypurine tract
sequence (or cppt) from the pol gene is included 5’ to PGK [42,46].
In conclusion, on the basis of the hypothesis that in-vivo abolition of HIV gene
action or disruption/excision of over 80% of proviral HIV DNA can abrogate HIV’s
innate fitness to replicate and survive, I engineer HIV-pol gene and HIV-1 whole gen-
ome specific Zinc Finger Nucleases (ZFNs) and advance the protocol for constructing
and pre-clinically testing lentiviral vectors that deliver and transduce a diploid copy of
either ZFN genotype (LV-2xZifHIV-polFN or LV- 2xZifHIV-polFN). LV-2xZifHIV-polFN
and LV- 2xZifHIV-1FN may offer the ex-vivo or even in-vivo experimental opportunity
to halt HIV replication functionally by directly abrogating HIV-pol gene action or dis-
rupting/excising over 80% of proviral HIV dsDNA from latently infected cells.
Additional material
Additional file 1: A detailed list of the Multi-Zif assembly targeting sequences of the SIV/HIV-pol-gene.
This file offers a list of the 114 ZFAs that target specific DNA sequences within the SIV/HIV-pol-gene; detailing their
alpha-helical recognition sequences and target DNA sites.
Additional file 2: Two ZFNs cleaving within the SIV/HIV-pol gene. This file offers a list of the two zinc finger
nucleases that specifically target and cleave within DNA sequences of the SIV/HIV-pol gene, detailing their alpha-
helical recognition sequences and target DNA sites.
Additional file 3: A detailed list of the 15 ZFN cleaving within the HIV-1 whole genome. This file offers a list
of the 15 zinc finger nucleases that specifically target and cleave within >18 DNA- bp-sequences of the HIV-1
whole genome; detailing their alpha helical recognition sequences, and target-DNA sites.
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